277 related articles for article (PubMed ID: 14749122)
1. Antiangiogenic therapy and tumor progression.
Blagosklonny MV
Cancer Cell; 2004 Jan; 5(1):13-7. PubMed ID: 14749122
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review).
Blagosklonny MV
Int J Oncol; 2001 Aug; 19(2):257-62. PubMed ID: 11445836
[TBL] [Abstract][Full Text] [Related]
3. Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIF‑1α pathway.
Kim A; Ma JY
Int J Oncol; 2018 Sep; 53(3):1160-1170. PubMed ID: 30015877
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
5. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Yeo EJ; Chun YS; Cho YS; Kim J; Lee JC; Kim MS; Park JW
J Natl Cancer Inst; 2003 Apr; 95(7):516-25. PubMed ID: 12671019
[TBL] [Abstract][Full Text] [Related]
6. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.
Rey S; Schito L; Wouters BG; Eliasof S; Kerbel RS
Trends Cancer; 2017 Jul; 3(7):529-541. PubMed ID: 28718406
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
[TBL] [Abstract][Full Text] [Related]
9. Targeting vasculogenic mimicry by phytochemicals: A potential opportunity for cancer therapy.
Haiaty S; Rashidi MR; Akbarzadeh M; Maroufi NF; Yousefi B; Nouri M
IUBMB Life; 2020 May; 72(5):825-841. PubMed ID: 32026601
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacin B inhibits tumor angiogenesis by triggering the mitochondrial signaling pathway in endothelial cells.
Piao XM; Gao F; Zhu JX; Wang LJ; Zhao X; Li X; Sheng MM; Zhang Y
Int J Mol Med; 2018 Aug; 42(2):1018-1025. PubMed ID: 29717773
[TBL] [Abstract][Full Text] [Related]
11. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
Welti J; Loges S; Dimmeler S; Carmeliet P
J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
[TBL] [Abstract][Full Text] [Related]
12. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Bottsford-Miller JN; Coleman RL; Sood AK
J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
[TBL] [Abstract][Full Text] [Related]
13. Overview of angiogenesis: Biologic implications for antiangiogenic therapy.
Ellis LM; Liu W; Ahmad SA; Fan F; Jung YD; Shaheen RM; Reinmuth N
Semin Oncol; 2001 Oct; 28(5 Suppl 16):94-104. PubMed ID: 11706401
[TBL] [Abstract][Full Text] [Related]
14. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo.
Chao WR; Amin K; Shi Y; Hobbs P; Tanabe M; Tanga M; Jong L; Collins N; Peters R; Laderoute K; Dinh D; Yean D; Hou C; Sato B; Alt C; Sambucetti L
Angiogenesis; 2011 Mar; 14(1):1-16. PubMed ID: 21104121
[TBL] [Abstract][Full Text] [Related]
15. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
[TBL] [Abstract][Full Text] [Related]
16. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
17. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
Jain RK; Tong RT; Munn LL
Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
[TBL] [Abstract][Full Text] [Related]
18. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
Li C; Liu T; Bazhin AV; Yang Y
J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
[TBL] [Abstract][Full Text] [Related]
19. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis.
DeNiro M; Alsmadi O; Al-Mohanna F
Exp Eye Res; 2009 Nov; 89(5):700-17. PubMed ID: 19580810
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to antiangiogenesis therapy.
Azam F; Mehta S; Harris AL
Eur J Cancer; 2010 May; 46(8):1323-32. PubMed ID: 20236818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
